Drivers of physician decision-making and patient perspectives across lines of therapy in multiple myeloma in the USA

Ribbands, Amanda; Boytsov, Natalie; Bailey, Abigail; Gorsh, Boris; Luke, Emily; Lambert, Alexandre

doi:10.2217/fon-2023-0020

Cited by 2 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Findings of this present study will benefit the development of a patient-centered treatment approach and shared decision-making between patients and physicians. It is important to note that priorities vary from patient to patient and may change as patients go through lines of therapy, as shown in our study and a recent survey by Ribbands et al ( 27 ). With rapidly expanding availability of new therapies, surveys and studies like ours will continue to shape the treatment landscape and ultimately, redefine the patient-physician discussion.…”

Section: Discussionsupporting

confidence: 55%

Patient perspectives on BCMA-targeted therapies for multiple myeloma: a survey conducted in a patient advocacy group

Hydren,

Lin,

Sweeney

et al. 2024

Front. Health Serv.

View full text Add to dashboard Cite

BackgroundAdvances in multiple myeloma (MM) treatment have shifted the therapeutic landscape. Understanding patients' perspectives can assist physicians in helping patients make informed decisions. This study aimed to understand the patient decision-making process and gain insights into patient perspectives on B-cell maturation antigen (BCMA)-targeted therapies for MM.MethodsAn 18-question survey was completed by patients with MM enrolled in HealthTree® Cure Hub, an online portal helping patients with plasma cell dyscrasias navigate their disease.ResultsFrom October 28, 2022, to January 12, 2023, 325 patients with MM participated in the survey. The mean age (standard deviation) of the respondents was 66 (8) years; 54% were female and 90% were White. Among 218 patients with complete clinical records in the database, the median (min, max) lines of therapy (LOT) was 2 (1,16). Among 61 (28%) patients who had received ≥4 LOTs, 55 (90%) were triple-class exposed. Of the 290 patients who responded to the question about openness to new therapies, 76 (26%) were open to trying a new therapy immediately and 125 (43%) wanted more information on safety and efficacy. Most respondents reported likely or very likely to try a BCMA CAR T-cell therapy (60%) or a bispecific antibody (74%) and some needed more information to decide (16% for CAR T-cell therapy and 13% for bispecific antibody). The most requested information included efficacy, side effects (SEs), eligibility, and administration process for both CAR T-cell and bispecific therapies. When 2 therapies with the same efficacy and duration of response were offered, 69% of respondents would prefer the therapy with a lower risk of severe SEs but requires continuous dosing with no treatment-free interval, and 31% preferred a therapy given once followed by a treatment-free interval but with a potentially higher risk of severe SEs. To receive an effective therapy, the top acceptable trade-offs included frequent monitoring of SEs and initiating a new therapy in a hospital setting, and the least acceptable compromise was caregiver burden.ConclusionsThis study found a high level of openness in patients with MM to try BCMA-targeted therapies. Information on efficacy, safety, availability, and eligibility may assist patients on decision-making.

show abstract

Section: Discussionsupporting

confidence: 55%

Patient perspectives on BCMA-targeted therapies for multiple myeloma: a survey conducted in a patient advocacy group

Hydren,

Lin,

Sweeney

et al. 2024

Front. Health Serv.

View full text Add to dashboard Cite

show abstract

Patient Perspectives on Social and Identity Factors Affecting Multiple Myeloma Care: Barriers and Opportunities

Neparidze,

Godara,

Lin

et al. 2024

Healthcare

View full text Add to dashboard Cite

Patients living with multiple myeloma (MM) have a substantial disease burden and face multiple barriers to care. Building upon our previous research using mixed methods, this focus group research aimed to identify patients’ priorities regarding specific social and identity-related needs, map these prioritized needs to the disease journey, and describe patient-generated ideas to improve patient support. Participants noted that patients with MM need a range of emotional, social, and financial support throughout the disease journey. They identified initial MM diagnosis and treatment adherence as two critical points in the MM journey where patients need the most support and assistance. The findings of this research suggest that overall, patients with MM need comprehensive support, ideally from a multidisciplinary team consisting of health care providers, patient advocates, social workers, and psychologists to help patients understand their disease and treatment options, make informed treatment decisions, adhere to treatment, and ultimately reduce their disease burden and improve outcomes. This research revealed that patients with MM need varying types and levels of support, with the most common needs including information on disease and treatment, connections to financial resources and support systems, assistance with navigating insurance options, and transportation and logistical support for medical appointments.

show abstract

Drivers of physician decision-making and patient perspectives across lines of therapy in multiple myeloma in the USA

Cited by 2 publications

References 22 publications

Patient perspectives on BCMA-targeted therapies for multiple myeloma: a survey conducted in a patient advocacy group

Patient perspectives on BCMA-targeted therapies for multiple myeloma: a survey conducted in a patient advocacy group

Patient Perspectives on Social and Identity Factors Affecting Multiple Myeloma Care: Barriers and Opportunities

Contact Info

Product

Resources

About